Dear colleagues and partners!

April 24 and May 12 - LABOR NUANCES DURING QUARANTINE: LET'S DOT THE "i"`s AND CROSS THE “t”`s (parts 1 and 2)

PART ONE1. The main options for adapting the work of workers in quarantine
2. Recent changes to the Labor Code in connection with the quarantine
3. Change of working conditions for the quarantine period. Legitimacy of acquaintance with new job responsibilities in electronic form
4. The issue of granting unpaid leave to the employee during quarantine
5. Introduction of part-time or downtime at the enterprise: registration and payment procedure
6. Dismissal during quarantine
7. The procedure for registration of distance work and its risks
8. Work remotely outside Ukraine
9. The use of irregular working hours - proper documentation and possible abuse?

PART 2
1. Trade unions and the problems they create
2. Transition to an electronic employee book
3. Dismissal based on test results - where non-obvious mistakes are made
4. Failure to take on the duties of a temporarily absent employee - when are the risks real?
5. The practice of companies and court decisions in the field of fixed-term employment contracts
6. Dismissal of an employee pursuant to paragraph 5 of part one of Article 41 of the Labor Code of Ukraine (termination of powers of officials) - problems of determining the "official", the grounds for dismissal of an official under this rule, conditions and procedure for dismissal
7. Common mistakes in written employment contracts and general recommendations
8. Other topical issues for pharmaceutical companies.

April 28 - ANTITRUST REGULATION OF THE PHARM

1. Antitrust risks of recent months or what to do with price monitoring?
2. Red lines of the AMCU on advertising of medicines - yesterday, today, tomorrow
3. Does the AMCU have a position on marketing contracts - an analysis of the practice of the last ten years
4. AMCU and distribution - anniversary of recommendation clarifications
5. AMCU and retail trade - gradual delineation of regulatory boundaries
6. Forecasts for the second half of 2020 or what to expect from the pharm?

April 29 and May 15 - RIGHT TO PROMO: LIMITS OF RISK (parts 1 and 2)

PART ONE
1. The legality of the functioning of supply services for the purchase of medicines. Ways to identify information on such sites
2. Ability to use (almost) the same names of different products in the company's line, including Rx
3. Restrictions on sponsorship materials and methods of "legalization"
4. Typical mistakes and problems in TV commercials, advertising slogans

PART TWO1. Comparative advertising
2. CASH back to buyers
3. Promotions related to photo checks
4. Advertising elements on drug packaging
5. Current requirements for labeling of dietary supplements according to the Law “On Consumer Information…”, recent practice of the AMCU on labeling.

May 5 - TAXATION OF MARKETING AND PHARMACY PROMOTION

1. Marketing costs - how to justify and defend (the relationship of costs and economic activity)
2. Use of intellectual property - risks of providing services to non-resident rights holders
3. The tax side of working with health professionals or something that has been forgotten in the industry for so long
4. VAT taxation of distribution of advertising, promotional and information materials
5. Basic strategies of taxation of PIT and OT distributions

May 18 - IMPORT AND DISTRIBUTION TAXATION

1. Discounts in the supply chain through the eyes of taxpayers and industry
2. How to prescribe and provide discounts as correctly as possible so as not to create tax risks
3. New changes in VAT on imports and supplies of medicine (our answer to coronavirus)
4. Related services of distributors - red lines and zones of uncertainty in the tax sphere
5. Transfer pricing of imports - how to minimize the risks of importing goods for the industry

May 8 - MARKETING AGREEMENTS WITH PHARMACIES: tax and legal nuances of conclusion and registration

1. How to prove the relationship of the counterparty with the pharmacy and its ability to provide marketing services
2. What is the market price for marketing services
3. What frequency of providing different types of marketing services is the least risky
4. How to justify the budget for marketing services in pharmacies (in particular, the need to attract third-party contractors, communication with business activities, correlation with sales)
5. Antitrust nuances of marketing services: what you should pay attention to when concluding marketing agreements

May 20 - NEW IN WORK WITH HEALTHCARE PROFESSIONALS

1. Anti-corruption aspects of working with POZ: categorization of POZ and restrictions on working with them
2. Tax aspects of POZ work: what to pay attention to when paying or paying for POZ
3. Selection of POZ to participate in various activities of pharmaceutical companies - as we design
4. Online work with POZ - a requirement of time and opportunities to reduce risks
5. Prospects for building work with POZ taking into account the latest changes

May 22 - TAXATION OF REPRESENTATIVE OFFICES - ABOUT ETERNAL IN THE PHARM

1. Why the use of representative offices is becoming increasingly problematic (even permanent)
2. Recent changes in the legislation and practice of tax audits regarding the recognition of representative offices as permanent
3. Amendments to the legislation on taxation of permanent representative offices, or time to change the form of presence
4. Transformation of representative offices - new formats in the light of recent legislative changes
5. Tax audits of representative offices - what and how to prepare - an algorithm of action
6. Appealing inspection results is the most effective strategy